Gossamer Bio and Respira Therapeutics have entered into an option agreement to develop Respira’s pulmonary hypertension treatment candidate RT234, Pulmonary Hypertension News, September 26, 2024

Gossamer Bio has an option to acquire Respira Therapeutics and its inhaled pulmonary arterial hypertension treatment RT234. Gossamer plans to develop RT234 for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), the same two indications for which it is already developing its own inhaled treatment candidate, seralutinib. RT234 is an inhaled formulation […]

Gossamer Bio and Respira Therapeutics have entered into an option agreement to develop Respira’s pulmonary hypertension treatment candidate RT234, Pulmonary Hypertension News, September 26, 2024 Read Post »

New study reveals how BMP-9 regulates lung vessels, opening doors for future pulmonary arterial hypertension therapies, new findings from a Franco-German study, Proceedings of the National Academy of Sciences of the USA (PNAS), July 2025

  Pulmonary arterial hypertension (PAH) happens when the blood vessels in the lungs become too narrow and stiff. This raises pressure in the lungs and puts strain on the heart. In a collaborative study, scientists from Inserm and Université Paris-Saclay in France, together with researchers from the Institute for Lung Health (ILH) in Germany, discovered

New study reveals how BMP-9 regulates lung vessels, opening doors for future pulmonary arterial hypertension therapies, new findings from a Franco-German study, Proceedings of the National Academy of Sciences of the USA (PNAS), July 2025 Read Post »

Allrock Bio Raises $50M to advance pulmonary arterial hypertension (PAH) and pulmonary hypertension due to interstitial lung disease (PH-ILD) Treatment ROC-101 into Phase 2a Trials

Allrock Bio raised $50M to fund Phase 2a trials of ROC-101, an oral treatment for pulmonary hypertension. The ROCSTAR trial will test ROC-101 combined with standard therapies in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to underlying interstitial lung disease (PH-ILD) patients, starting late 2025. ROC-101 blocks ROCK1 and ROCK2 proteins to reduce inflammation,

Allrock Bio Raises $50M to advance pulmonary arterial hypertension (PAH) and pulmonary hypertension due to interstitial lung disease (PH-ILD) Treatment ROC-101 into Phase 2a Trials Read Post »

Data on investigational treprostinil transdermal patch system to be presented at professional symposium organised by the US Pulmonary Hypertension Association, September 18-20, 2025

Corsair Pharma will present preclinical data on their TRX-248 transdermal patch at the Pulmonary Hypertension Professional Network Symposium (PHPPN), Sept 18-20, 2025. The once-daily patch delivers treprostinil for pulmonary arterial hypertension treatment. These data provide additional support for the clinical program which is currently in a first-in-human Phase 1 study. The transdermal patch has the

Data on investigational treprostinil transdermal patch system to be presented at professional symposium organised by the US Pulmonary Hypertension Association, September 18-20, 2025 Read Post »

TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis, September 2, 2025

United Therapeutics has announced that the pivotal TETON-2 study of nebulized Tyvaso® (treprostinil) for the treatment of idiopathic pulmonary fibrosis (WHO Group III) met its primary endpoint—and several key secondary endpoints—with statistical significance. Read more on the press release at this link

TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis, September 2, 2025 Read Post »

Tool identifies degree of 1-year mortality risk in patients with pulmonary hypertension due to underlying lung disease, Healio, August 26, 2025

Risk scores designed for pulmonary arterial hypertension (Group I of the World Health Organisation classification for pulmonary hypertension) do not adequately account for the unique pathophysiology seen in patients whose pulmonary hypertension arises from underlying lung disease (Group III of the World Health Organisation (WHO) classification). This is the rationale behind a retrospective study of

Tool identifies degree of 1-year mortality risk in patients with pulmonary hypertension due to underlying lung disease, Healio, August 26, 2025 Read Post »

Cereno Scientific Granted FDA Fast Track Designation for CS1 Investigational Drug for Pulmonary Arterial Hypertension (PAH)

Cereno Scientific announced on August 26, 2025 that the US Food and Drug Administration (FDA) has granted Fast Track designation to CS1, its lead drug candidate for treating pulmonary arterial hypertension (PAH). This designation accelerates development and regulatory review for treatments addressing serious conditions with high unmet medical need. In a Phase IIa trial, it

Cereno Scientific Granted FDA Fast Track Designation for CS1 Investigational Drug for Pulmonary Arterial Hypertension (PAH) Read Post »

The causal effect of gut microbiome on pulmonary artery hypertension based on a two-sample Mendelian randomization study, Nutrition & Metabolism, July 29, 2025

Previous studies have shown that pulmonary arterial hypertension patients have different gut bacteria compositions, with lower diversity and fewer anti-inflammatory bacteria that produce beneficial short-chain fatty acids. Could the gut-lung connection contribute to pulmonary arterial hypertension development through enhanced nerve communication and altered bacterial metabolites like trimethylamine-N-oxide? In this two-sample Mendelian randomization study, recently published

The causal effect of gut microbiome on pulmonary artery hypertension based on a two-sample Mendelian randomization study, Nutrition & Metabolism, July 29, 2025 Read Post »

Real-life use of quality of life questionnaires in pulmonary arterial hypertension in Spain, European Journal of Cardiovascular Nursing, July 7, 2025

Despite strong recommendations to assess quality of life in pulmonary arterial hypertension patients from the World Symposia on Pulmonary Hypertension (WSPH) in 2018 and 2024, and from the 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) joint pulmonary hypertension guidelines, this evaluation remains rarely implemented in clinical practice. This cross-sectional study of

Real-life use of quality of life questionnaires in pulmonary arterial hypertension in Spain, European Journal of Cardiovascular Nursing, July 7, 2025 Read Post »

Pulmonary endarterectomy vs balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension, BMC Pulmonary Medicine, August 6, 2025

A study recently published on BMC Pulmonary Medicine compared baseline characteristics and short-term efficacy of pulmonary endarterectomy (gold standard for operable chronic thromboembolic pulmonary hypertension, removing thickened intima and organized thrombus from pulmonary arteries) vs. balloon pulmonary angioplasty (an option for inoperable chronic thromboembolic pulmonary hypertension, improving blood flow by dilating stenosed/occluded vessels without removing lesions), particularly

Pulmonary endarterectomy vs balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension, BMC Pulmonary Medicine, August 6, 2025 Read Post »

Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension, Pulmonary Circulation, July 18, 2025

The Research: Evidence on the predictive ability of risk assessment models for event-free survival (EFS) in patients with pulmonary arterial hypertension is scarce, say the authors of a recent study published on Pulmonary Circulation. The aim of the study was to evaluate how well three different risk assessment models predict event-free survival. The study included 411

Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension, Pulmonary Circulation, July 18, 2025 Read Post »

Pulmonary Artery Denervation for Idiopathic Pulmonary Arterial Hypertension: A Case Report, Catheterization & Cardiovascular Interventions (CCI), July 29, 2025

Current targeted medications for pulmonary arterial hypertension can help symptoms but have limited long-term effectiveness and often cause significant side effects and high costs. Percutaneous pulmonary artery denervation is a realtively new interventional procedure that selectively destroys sympathetic nerves to restore nerve and hormone balance in patients who don’t respond well to standard medications – see

Pulmonary Artery Denervation for Idiopathic Pulmonary Arterial Hypertension: A Case Report, Catheterization & Cardiovascular Interventions (CCI), July 29, 2025 Read Post »

Inflammation and Weight in Pulmonary Hypertension – Surprising Differences in Outcomes, American Journal of Respiratory and Critical Care Medicine, August 6, 2025

A recent study titled “Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes” analysed two common health factors in people with pulmonary hypertension: inflammation and body weight. Inflammation is associated with all types of pulmonary hypertension. In the study inflammation was measured by a blood test called C-reactive protein (CRP), and body

Inflammation and Weight in Pulmonary Hypertension – Surprising Differences in Outcomes, American Journal of Respiratory and Critical Care Medicine, August 6, 2025 Read Post »

New study finds possible diagnostic biomarkers for idiopathic pulmonary arterial hypertension, Pulmonary Hypertension News, July 12, 2025

Researchers have found two specific genes — PRDX1 and TNFAIP3 — whose activity levels could serve as diagnostic biomarkers that could help doctors detect idiopathic pulmonary arterial hypertension (IPAH) earlier and possibly guide treatment. This study, published in Scientific Reports on July 12, 2025, focused on genes linked to ferroptosis, an iron-dependent type of cell

New study finds possible diagnostic biomarkers for idiopathic pulmonary arterial hypertension, Pulmonary Hypertension News, July 12, 2025 Read Post »

Programmed Cell Death: A Pivotal Player in Pulmonary Arterial Hypertension, European Journal of Pharmacology, July 8, 2025

In pulmonary arterial hypertension (PAH) lung blood vessel cells grow excessively, increasing vascular resistance and ultimately leading to right heart failure. While researchers understand many molecular mechanisms behind pulmonary arterial hypertension, effective treatments remain limited. Programmed cell death (PCD) plays a crucial role in the pathogenesis of various diseases, including cancer, chronic conditions, cardiovascular disorders,

Programmed Cell Death: A Pivotal Player in Pulmonary Arterial Hypertension, European Journal of Pharmacology, July 8, 2025 Read Post »

Why negative trials in pulmonary arterial hypertension should be made public, Current Opinion in Pulmonary Medicine, July 8, 2025

A review published on Current Opinion in Pulmonary Medicine on July 8, 2025 examines recent negative clinical trials in pulmonary arterial hypertension (PAH) research, emphasizing the valuable insights these studies provide despite their unsuccessful outcomes. The article reviews several recent negative trials testing various therapeutic approaches in pulmonary arterial hypertension, including tocilizumab (an anti-inflammatory drug),

Why negative trials in pulmonary arterial hypertension should be made public, Current Opinion in Pulmonary Medicine, July 8, 2025 Read Post »

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025

The key findings from the Pulmonary Hypertension Global Patient Survey (PHGPS) adult cohort of 3,329 patients have been published in the ERJ Open Research 2025, highlighting the achievements, shortcomings & regional disparities of clinical care & research globally. The Pulmonary Hypertension Global Patient Survey represents the most extensive survey of its type in the pulmonary

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025 Read Post »

Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025

Ralinepag is a novel prostacyclin receptor agonist. It is designed to mimic prostacyclin, a molecule that reduces blood pressure by relaxing blood vessels. It is a once-daily oral formulation. United Therapeutics has announced the completion of enrollment for its ADVANCE OUTCOMES, a Phase 3 clinical trial testing ralinepag for pulmonary arterial hypertension (PAH). The study

Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025 Read Post »

The landscape of referrals for lung transplantation in pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry, Journal of Heart and Lung Transplantation, June 26, 2025

A large US registry study of 1,671 patients with pulmonary arterial hypertension (PAH) over 4607 person-years of follow up found that lung transplant referrals are occurring far too infrequently and too late in the disease course. Despite professional society recommendations for early referral, only 12% of patients were referred for transplantation over the study period.

The landscape of referrals for lung transplantation in pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry, Journal of Heart and Lung Transplantation, June 26, 2025 Read Post »

Scientists create first mini-lungs with built-in blood vessels, unlocking new insights for pulmonary vascular disease, UCLA Newsroom, July 2, 2025

Researchers at the University of California, Los Angeles (UCLA), have achieved a breakthrough by successfully growing miniature lungs from stem cells that include functioning blood vessel networks for the first time. Published in Cell, this advancement represents a significant step forward because previous lung organoids lacked the essential vascular systems needed for proper lung function.

Scientists create first mini-lungs with built-in blood vessels, unlocking new insights for pulmonary vascular disease, UCLA Newsroom, July 2, 2025 Read Post »

TRANSLATE »
Scroll to Top